Search results for Capecitabine - Clinical Trials Registry

Example: Heart Attack

Search clinical trials for: Capecitabine

Total 1481 results

NCT05152147

Recruiting

A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers

Conditions: Gastric Neoplasms, Gastroesophageal Adenocarcinoma, Esophageal Adenocarcinoma
NCT04034251

Recruiting

Intraperitoneal and Intravenous Paclitaxel Chemotherapy With Oral Capecitabine for Gastric Adenocarcinoma With Peritoneal Carcinomatosis

Conditions: Gastric Adenocarcinoma, Gastric Cancer, Esophagogastric Junction, Peritoneal Carcinomatosis
NCT04304209

Active, not recruiting

Pd1 Antibody Sintilimab ± Chemoradiotherapy for Locally Advanced Rectal Cancer

Conditions: Colorectal Cancer Stage II, Colorectal Cancer Stage III
NCT02892123

Active, not recruiting

Trial of ZW25 (Zanidatamab) in Patients With Advanced HER2-expressing Cancers

Conditions: HER2-expressing Cancers
NCT01494662

Active, not recruiting

HKI-272 for HER2-Positive Breast Cancer and Brain Metastases

Conditions: Breast Cancer
NCT05609370

Recruiting

A Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Capecitabine Versus Bevacizumab Plus Capecitabine in Participants With Unresectable or Metastatic Colorectal Cancer

Conditions: Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer
NCT05249101

Recruiting

A Study of Ivaltinostat Plus Capecitabine or Capecitabine in Metastatic Pancreatic Adenocarcinoma

Conditions: Metastatic Pancreatic Adenocarcinoma
NCT05648006

Not yet recruiting

First-line Maintenance of OH2 Injection for Advanced Colorectal Cancer

Conditions: Advanced Colorectal Carcinoma
NCT02767661

Active, not recruiting

Metronomic Capecitabine Plus Aromatase Inhibitor for First Line Treatment in HR(+), Her2(-) Metastatic Breast Cancer

Conditions: Breast Cancer
NCT05633654

Recruiting

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy

Conditions: Triple Negative Breast Cancer
NCT05007106

Recruiting

MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005)

Conditions: Uterine Cervical Neoplasms, Endometrial Neoplasms, Squamous Cell Carcinoma of Head and Neck, Gallbladder Neoplasms, Cholangiocarcinoma, Esophageal Neoplasms, Triple Negative Breast Neoplasms, Hepatocellular Carcinoma, Urinary Bladder Neoplasms, Ovarian Neoplasms, Stomach Neoplasms
NCT04929028

Recruiting

Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer

Conditions: AIDS-Related Anal Carcinoma, Anal Basaloid Carcinoma, Anal Canal Cloacogenic Carcinoma, Anal Margin Squamous Cell Carcinoma, Anal Squamous Cell Carcinoma, HIV Infection, Rectal Squamous Cell Carcinoma, Stage I Anal Cancer AJCC v8, Stage II Anal Cancer AJCC v8, Stage II Rectal Cancer AJCC v8, Stage IIA Anal Cancer AJCC v8, Stage IIA Rectal Cancer AJCC v8, Stage IIB Anal Cancer AJCC v8, Stage IIB Rectal Cancer AJCC v8, Stage IIC Rectal Cancer AJCC v8, Stage III Anal Cancer AJCC v8, Stage III Rectal Cancer AJCC v8, Stage IIIA Anal Cancer AJCC v8, Stage IIIA Rectal Cancer AJCC v8, Stage IIIB Anal Cancer AJCC v8, Stage IIIB Rectal Cancer AJCC v8, Stage IIIC Anal Cancer AJCC v8, Stage IIIC Rectal Cancer AJCC v8
NCT04607421

Recruiting

A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer

Conditions: Neoplasms
NCT05699746

Not yet recruiting

CAPEOX vs Observation in Colorectal Cancer Patients With Positive MRD

Conditions: Colorectal Cancer
NCT05700656

Not yet recruiting

Galunisertib Combined With Capecitabine in Advanced CRC With PM

Conditions: Colorectal Cancer Metastatic, Peritoneal Carcinomatosis
NCT04534218

Active, not recruiting

Regorafenib in Combination With Metronomic Chemotherapies, and Low-dose Aspirin in Metastatic Colorectal Cancer

Conditions: Colo-rectal Cancer, Metastatic Cancer
NCT03073785

Recruiting

Hypofractionated Stereotactic Body Radiation Therapy and Fluorouracil or Capecitabine With or Without Zoledronic Acid in Treating Patients With Locally Advanced Pancreatic Cancer

Conditions: Pancreatic Adenocarcinoma, Recurrent Pancreatic Carcinoma, Stage I Pancreatic Cancer AJCC v6 and v7, Stage IA Pancreatic Cancer AJCC v6 and v7, Stage IB Pancreatic Cancer AJCC v6 and v7, Stage II Pancreatic Cancer AJCC v6 and v7, Stage IIA Pancreatic Cancer AJCC v6 and v7, Stage IIB Pancreatic Cancer AJCC v6 and v7, Stage III Pancreatic Cancer AJCC v6 and v7, Stage IV Pancreatic Cancer AJCC v6 and v7
NCT02170090

Active, not recruiting

Adjuvant Chemotherapy With Gemcitabine and Cisplatin Compared to Standard of Care After Curative Intent Resection of Biliary Tract Cancer

Conditions: Cholangiocarcinoma, Gall Bladder Carcinoma
NCT04703101

Recruiting

Short Course Radiation Therapy and Combination Chemotherapy for the Treatment of Stage II-III Rectal Cancer

Conditions: Locally Advanced Rectal Carcinoma, Rectal Adenocarcinoma, Stage II Rectal Cancer AJCC v8, Stage IIA Rectal Cancer AJCC v8, Stage IIB Rectal Cancer AJCC v8, Stage IIC Rectal Cancer AJCC v8, Stage III Rectal Cancer AJCC v8, Stage IIIA Rectal Cancer AJCC v8, Stage IIIB Rectal Cancer AJCC v8, Stage IIIC Rectal Cancer AJCC v8
NCT04662710

Recruiting

Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) Plus Chemotherapy in Participants With Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-7902-015/E7080-G000-321/LEAP-015)

Conditions: Advanced/Metastatic Gastroesophageal Adenocarcinoma
NCT05693766

Not yet recruiting

Gene Signatures to Guide HR+MBC Therapy in a Diverse Cohort

Conditions: Invasive Mammary Carcinoma, Metastatic Breast Cancer
NCT04895358

Recruiting

Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)

Conditions: Breast Neoplasms
NCT05374512

Recruiting

A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)

Conditions: Breast Cancer
NCT04158258

Active, not recruiting

A Study to Describe the Diagnosis, Anti-Cancer Treatment and Clinical Outcome in Patients With Newly Diagnosed Breast Cancer in Latin America

Conditions: Breast Cancer
NCT03342937

Active, not recruiting

KeyLargo: Pembrolizumab + Oxaliplatin + Capecitabine in Gastric Cancer

Conditions: Gastric Cancer, Esophagus Cancer

Search clinical trials for: Capecitabine

Sponsors and Collaborators

Medical Conditions

Drug Interventions

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations